Innate Pharma (IPHA) Current Deferred Revenue (2017 - 2025)

Innate Pharma (IPHA) has disclosed Current Deferred Revenue for 8 consecutive years, with $658254.8 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Current Deferred Revenue fell 89.57% year-over-year to $658254.8, compared with a TTM value of $658254.8 through Dec 2024, down 89.57%, and an annual FY2024 reading of $666720.4, down 89.49% over the prior year.
  • Current Deferred Revenue was $658254.8 for Q4 2024 at Innate Pharma, down from $6.3 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $14.3 million in Q4 2021 and bottomed at $658254.8 in Q4 2024.
  • Average Current Deferred Revenue over 5 years is $8.3 million, with a median of $6.7 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue rose 6.15% in 2021, then plummeted 89.57% in 2024.
  • Year by year, Current Deferred Revenue stood at $13.5 million in 2020, then rose by 6.15% to $14.3 million in 2021, then crashed by 53.2% to $6.7 million in 2022, then dropped by 5.71% to $6.3 million in 2023, then tumbled by 89.57% to $658254.8 in 2024.
  • Business Quant data shows Current Deferred Revenue for IPHA at $658254.8 in Q4 2024, $6.3 million in Q4 2023, and $6.7 million in Q4 2022.